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ment, we performed a screening of transcription factors using a promoter
assay of COL10A1 gene, and identiﬁed hypoxia-inducible factor 2α (HIF2A;
encoded by EPAS1) as the most potent transactivator. HIF2A enhanced
promoter activities of not only COL10A1, but also MMP13 and VEGF through
speciﬁc binding to the respective hypoxia-responsive elements. HIF2A,
independently of the oxygen-dependent hydroxylation, was essential for
endochondral ossiﬁcation of cultured chondrocytes and embryonic skeletal
growth in mice. HIF2A was induced in osteoarthritic cartilages of mice
and humans. The HIF2A heterozygous deﬁcient mice exhibited resistance
to OA development, and a functional SNP in the human HIF2A gene was
associated with knee OA in a Japanese population. Hence, HIF2A is an ex-
tensive transactivator during endochondral ossiﬁcation, and may represent
a therapeutic target for OA.
In addition to HIF2A, recent mouse genetic approaches by others and
us found that other endochondral ossiﬁcation signals like Runx2, C/EBPβ,
carminerin, osteoprotegerin, β-catenin, syndecan-4, hedgehog, etc. are in-
volved in the OA development. The proteinases produced during the
endochondral ossiﬁcation process are likely to cause cartilage degradation
at the center of the joint and osteophyte formation at the periphery.
The difference of the two sites may depend on the vascularity. At the
periphery, vascularity is accessible from the synovium or tendon, which
completes endochondral ossiﬁcation and forms osteophytes, just as it does
during skeletal growth and fracture healing. However, in the center, the
vascularity is not accessible from the edge, so that it may end up with
cartilage degradation without being replaced by bone. Molecules related
to the endochondral ossiﬁcation signals might become therapeutic targets
altering the course of this disabling disease.
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IMAGING IN OA: WHAT HAVEWE LEARNED ANDWHERE AREWE GOING?
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Purpose: Osteoarthritis (OA) is the leading cause of musculoskeletal dis-
ability with few conventional and surgical treatment options. Although
advanced imaging techniques are presently not applied in a clinical routine
setting for diagnostic purposes, rapid technical developments in mag-
netic resonance imaging (MRI) and application of image post-processing
methodology in combination with longitudinal studies applying MRI to
large cohorts have contributed greatly to disease understanding in recent
years. Focus of this presentation will be an overview of the role of MRI
A.) clinically including differential diagnosis and longitudinal monitoring of
disease on a patient level, B.) as a surrogate outcome measure for structural
endpoints in clinical studies, including efforts to isolate patients at greatest
risk for progression and C.) in understanding OA symptoms. In addition, the
current role of conventional radiography and other less commonly applied
methods will be re-discussed. As the vast majority of ongoing research in
OA imaging is focusing on the knee joint, the center of this overview will
also be the knee.
Methods: The radiographic examination of joints is still useful to establish
a diagnosis of OA and still holds an important role for deﬁning inclusion
criteria into clinical trials. Furthermore, radiographically detected joint
space narrowing is still the only accepted imaging outcome measure
in trials assessing disease modifying osteoarthritis drugs (DMOADs). The
current role of radiography will be discussed and advances in technology
of joint space width assessment will be presented.
The role of MRI has evolved rapidly over recent years. In the context
of joint imaging, cartilage imaging seems to be at the forefront of these
developments. Especially compositional MRI of cartilage ultrastructure has
lead to understanding of early, potentially reversible pathology. Advances
in quantitative morphologic cartilage assessment including novel ana-
lytic approaches have further added largely to understanding of disease
progression in recent years.
Due to MRI a change in paradigm has occurred in that it seems accepted
consensus now to perceive OA not as a disease of cartilage only but as
a whole-organ disorder involving multiple joint tissues leading eventually
to joint failure. Whole organ MRI assessment has contributed a lot to this
change in perception and will be discussed in detail. Many different joint
structures are of relevance in a clinical context and for disease progression.
Despite cartilage, most important seem to be the menisci, the subchondral
bone, ligamentous structures and the synovium. A consensus-based sugges-
tion for an MRI deﬁnition of early or pre-OA and deﬁnite OA is presented
in light of upcoming analyses of the large MRI datasets. Although MRI is
the most important methodology in imaging of OA and cartilage, other
modalities such as ultrasound, FDG-PET and computed tomography (CT)
do play a potentially important complimentary role that will be touched
brieﬂy.
Conclusions: The ﬁeld of imaging in OA and cartilage has evolved rapidly
and despite the continued lack of eﬃcient therapies there is hope that
especially imaging might be in a position to eventually drive therapeu-
tic break through. Publicly available OAI MRI data together with other
presently ongoing large epidemiological studies should allow the research
community to rapidly advance in understanding the natural course of the
disease and deﬁne risk factors relevant for OA disease progression. Current
data suggests that stratiﬁcation of risk is feasible to ascertain those at risk
for rapid progression using a number of different imaging-based metrics
including knee alignment, meniscal damage, bone marrow lesions, possibly
synovitis and joint effusion, and late stage disease. Identifying persons at
greatest risk for progression has important implications for clinical trial
planning and may possibly enhance study eﬃciency.
Eventually imaging and foremost MRI will be applied as surrogate measures
of disease progression, particularly in therapeutic intervention trials. Once
the clinical importance of these imaging endpoints is established, additional
advances in technology will drive a more comprehensive analysis of car-
tilage morphology, composition and other articular tissue pathology than
currently possible. This will be of particular importance once structure-
or disease-modifying interventions become available, as this will require
monitoring treatment response in large sets of OA patients. Only through
the availability of such interventions imaging will eventually play a relevant
and important role in clinical decision making and clinical practice.
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The menisci are two semi-circular ﬁbrocartilage structures positioned be-
tween the joint surfaces of the femur and tibia in the medial and lateral
knee joint compartments. Each meniscus covers approximately two-thirds
of the corresponding articular surface of the tibia. The menisci play a
critical protective role for the knee joint through shock absorption and load
distribution. When the knee is loaded, the tensile strength of the meniscal
matrix counteracts extrusion of the meniscus, and the meniscus distributes
stress over a large area of the articular cartilage; the healthy meniscus
mainly responds to load with compression. Loss of meniscal function by
meniscal tear or surgical removal of meniscal tissue has been strongly
associated with the development of radiographic knee osteoarthritis (OA).
Meniscal lesions have also been strongly linked to e.g. cartilage loss and
the development of subchondral bone marrow lesions which are both
prominent features of the disorder.
Meniscal lesions are regular ﬁndings on magnetic resonance imaging (MRI)
of the knee, especially in knees with OA typically in the form of horizontal,
ﬂap, and (or) complex tears, meniscal maceration, destruction or extru-
Figure 1. Prevalence of meniscal tear or maceration/destruction in the right knee among
991 middle-aged and elderly persons from the general population in Framingham, MA,
USA, according to age group and sex (all persons with previous knee surgery were ex-
cluded from the prevalence estimates of meniscal maceration/destruction) (Englund et
al. N Engl J Med. 2008 Sep 11;359[11]:1108-15).
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sion. However, asymptomatic meniscal lesions are common and frequent
incidental ﬁndings on knee MRI of the middle-aged or older patient.
Even though meniscal lesions cannot be viewed as an innocent bystander,
its linkage with knee symptoms is complex. Other knee pathologies than
meniscus tears may often be the direct cause of knee pain. Further, the high
frequency of meniscal pathology in the general population challenges the
health professional in choosing the best treatment in the short- and long-
term. A meniscal tear can lead to knee OA by increased focal biomechanical
loading, but knee OA can also lead to meniscal tear. A degenerative menis-
cal lesion in the middle-aged or older patient could suggest early-stage
pre-radiographic knee OA and should be treated accordingly. The need for
surgical treatment of stable degenerative meniscal lesions in knees with
or without OA is often doubtful and evidence of a beneﬁcial effect above
placebo is so far lacking. Surgical resection of stable meniscal lesions is not
expected to improve meniscal functioning.
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Purpose: Osteoarthritis (OA) is one the most common forms of joint dis-
ease in humans and companion animals. The management of OA primarily
focuses on symptomatic pain relief using analgesics and non-steroidal
anti-inﬂammatory drugs (NSAIDs). However, pharmacotherapy with con-
ventional drugs does not inﬂuence the course of disease progression and
is associated with signiﬁcant side effects in other organ systems. Conse-
quently, there is an acute need for developing safer alternative remedies
for OA. Self-management, complementary and alternative medicine strate-
gies are receiving increasing attention from patients, practitioners and
researchers. There are many biological pathways and molecular mech-
anisms by which dietary and nutritional factors might be expected to
exert favourable inﬂuences on pathophysiological processes in cartilage
and synovium in OA. However, these are poorly understood and the quality
and consistency of research on dietary supplements and nutraceuticals has
been variable. Research in our laboratory has focussed on testing a range
of botanicals and nutritional supplements in vitro. Our current objective is
to apply high throughput post-genomic techniques to identify the major
biomarkers present in the secretome of articular cartilage and monitor
responses to pro-inﬂammatory and anti-inﬂammatory stimuli.
Methods: We have established in vitro models of canine and equine
cartilage for screening plant-derived phytochemicals such as curcumin
and cocktails of plant extracts for anti-inﬂammatory activity. Our pre-
ferred model uses cartilage explants and incorporates viability and cy-
totoxicity assays (LIVE/DEAD®) as well as glycosaminoglycan (GAG) and
prostaglandin E2 (PGE2) release assays for assessing in vitro responses
to pro-inﬂammatory cytokines, NSAIDs, nutraceuticals and plant extracts.
We have also developed high throughput proteomic techniques to map
the secretome and identify a set of biomarkers for assessing extracellular
matrix turnover.
Results: Cell viability, GAG and PGE2 release appear to be consistent and
robust parameters for assessing the safety and anti-inﬂammatory activity
of NSAIDs, plant extracts and dietary supplements on cartilage explants
in vitro. The biomarkers identiﬁed from the secretome of both species
include cartilage oligomeric matrix protein (COMP) a well established
prognostic indicator and disease marker as well as ﬁbronectin, biglycan,
chondroadherin (CHAD), matrix metalloproteinases 1 and 3 (MMP-1, MMP-
3), clusterin, decorin, thrombospondins 1 and 4 (TSP-1, TSP-4), cartilage
intermediate layer protein -1 (CILP-1) and aggrecan core protein.
Conclusions: Dietary supplementation may well have a role in inﬂuencing
the course of OA progression. However, the scientiﬁc and medical commu-
nity remains skeptical about the eﬃcacy of nutritional supplementation for
OA despite their broad acceptance and use by patients. New and innovative
approaches are needed to gain a better understanding of the response to
NSAIDs and dietary supplements that claim to have anti-inﬂammatory ac-
tivity. Our work suggests that 3-dimensional culture systems may be used
to screen for anti-inﬂammatory activity in extracts of dietary supplements.
This approach combines viability/cytotoxicity tests, biochemical assays and
proteomics. We are currently validating quantitative western blot assays
for measuring changes in the levels of the protein biomarkers identiﬁed in
the cartilage secretome in response to inﬂammatory and anti-inﬂammatory
stimuli. We are also hoping to set up multiplex assays for other inﬂamma-
tory mediators. Once established, these assays may be applied to synovial
ﬂuid and serum samples from animals on clinical or ﬁeld trials of dietary
supplements. Whether dietary supplements can be effectively and safely
recommended to reduce NSAID usage is still unclear and requires more
rigorous research. Multi-disciplinary approaches that combine hypothesis
driven and well-designed basic, clinical and epidemiological studies should
help us make better-informed decisions about the beneﬁts of dietary
supplements in OA therapy.
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Research Council (EPSRC), the WALTHAM Centre for Pet Nutrition, the
Wellcome Trust and the National Centre for the Replacement, Reﬁnement
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The obstacles to overcome in rehabilitation of osteoarthritis must reﬂect
both the eliciting factors and practical issues with the implementation of
the program. The biomechanics of the knee may be the key to understand-
ing progression of knee OA. However, in a setting with varying degree of
joint destruction, pain, and loss of muscle strength, all three factors should
be considered by the therapist. On top of this, rehabilitation is an art of
interpersonal relationships.
It is very diﬃcult to sort out the best strategy for maintaining rehabil-
itation in patients with painful degenerative diseases [1]. The chance of
a rehabilitation program increases with the enthusiasm of both patient
and therapist. This evasive factor may to some extent be supported by
participation in a trial.
Before exercise - weight loss? While it is debated whether increased
weight per se may cause OA [2], once there, the weight seems to be
a decisive factor for progression, biomechanically driven by increased
joint loads, e.g. assesses by the knee adduction moment [3]. Weight may
inﬂuence gait by changes in peak adduction moment, muscle strength and
walking distance.
During exercise - treating the pain? To participate in e.g. exercises for a
painful disease, it must be considered whether the level of pain should
guide the therapy. This is all the more relevant as exercises may induce a
deterioration of the OA in some cases [4]. In favour of this strategy is the
central inhibition of muscle function [5]. On the other hand, reduction of
pain may cause changes in gait pattern with a potential for joint destruction
[6].
The interesting question is, whether a knee may become too bad for
exercise, i.e. if there is a ‘point-of-no-return’ for knee OA, with a unde-
sirable response in joint loading to pain at advanced stages of disease
(Henriksen et al. submitted). The interaction between structural changes,
pain, joint loadings and muscle function must be explored to improve
clinical outcomes of rehabilitation programmes.
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